c-erbB-4 protein expression in human breast cancer
Open Access
- 1 March 2000
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 82 (6) , 1163-1170
- https://doi.org/10.1054/bjoc.1999.1057
Abstract
The Type 1 family of growth factor receptors includes epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3 and c-erbB-4. Overexpression of the first two members is associated with poorer prognosis in patients with breast carcinoma. In this study we examined the expression of c-erbB-4 protein using the monoclonal antibody HFR-1. A total of 127 consecutive cases of primary operable invasive breast carcinoma presenting between 1975 and 1977 were studied. All patients were managed by simple mastectomy or conservation surgery with radiotherapy and no adjuvant therapy given. Long-term follow-up was maintained. Routine, formalin-fixed, paraffin-embedded tumour samples were used and sections were stained immunohistochemically using the Duet StreptABC method. Immunoreactivity was classified using a simple semi-quantitative scoring method. Protein expression was generally low but definite positive cytoplasmic, membranous and nuclear reactivity was identified in 58%, 41% and 25% of cases respectively. Expression at all three sites demonstrated significant inverse associations were histological grade. In addition, membrane accentuation correlated inversely with the Nottingham Prognostic Index (NPI), while cytoplasmic reactivity showed a positive association with c-erbB-3 expression. No significant associations were found with disease-free interval or survival. The results of this study demonstrate that higher levels of c-erbB-4 protein expression are associated with a more differentiated histological phenotype in contrast to the other members of the Type 1 family. Larger series with extended follow-up will be required to ascertain definitively the prognostic value of c-erbB-4 expression in breast carcinoma. © 2000 Cancer Research CampaignKeywords
This publication has 43 references indexed in Scilit:
- Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long‐term follow‐upHistopathology, 1992
- Identification of Heregulin, a Specific Activator of p185 erbB2Science, 1992
- The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients*Endocrine Reviews, 1992
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- c-erbB-2 oncoprotein expression in primary and advanced breast cancerBritish Journal of Cancer, 1991
- Expression of epidermal growth factor receptor in breast carcinoma.Journal of Clinical Pathology, 1990
- Epidermal growth factor (EGF) receptor gene transcription. Requirement for Sp1 and an EGF receptor-specific factor.Journal of Biological Chemistry, 1988
- Confirmation of a prognostic index in primary breast cancerBritish Journal of Cancer, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- A prognostic index in primary breast cancerBritish Journal of Cancer, 1982